Genmab A/S (GNMSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Genmab A/S (GNMSF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 55/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Genmab A/S (GNMSF) Resumen de Asistencia Médica y Tuberías
Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases. With a diverse portfolio of marketed products like DARZALEX and a robust pipeline, Genmab competes in the global biotechnology market, leveraging strategic collaborations to expand its reach and development capabilities.
Tesis de Inversión
Genmab A/S presents a notable research candidate within the biotechnology sector, driven by its innovative antibody therapeutics platform and strong pipeline. The company's marketed products, including DARZALEX, generate significant revenue, contributing to a profit margin of 16.7% and a gross margin of 93.6%. Growth catalysts include the continued expansion of DARZALEX in multiple myeloma and other indications, as well as the potential approval and commercialization of pipeline assets like epcoritamab. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. With a market capitalization of $16.97 billion and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market position. The company's beta of 0.75 suggests lower volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $16.97 billion, reflecting investor confidence in its antibody therapeutics platform.
- Profit margin of 16.7%, indicating efficient operations and strong profitability.
- Gross margin of 93.6%, highlighting the high value of its products and effective cost management.
- P/E ratio of 25.88, suggesting a premium valuation based on future growth expectations.
- Beta of 0.75, indicating lower volatility compared to the broader market.
Competidores y Pares
Fortalezas
- Innovative antibody therapeutics platform.
- Strong pipeline of products in development.
- Established market presence with marketed products.
- Strategic collaborations with leading pharmaceutical companies.
Debilidades
- Reliance on key products like DARZALEX.
- High R&D spending.
- Dependence on collaborations for commercialization.
- Exposure to clinical trial risks.
Catalizadores
- Ongoing: Continued expansion of DARZALEX in multiple myeloma and other indications.
- Upcoming: Potential approval and commercialization of epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
- Ongoing: Advancement of pipeline assets through clinical trials.
- Ongoing: Strategic collaborations with leading pharmaceutical and biotechnology companies.
- Upcoming: Potential for geographic expansion into new markets.
Riesgos
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles and delays.
- Ongoing: Competition from other biotechnology companies.
- Potential: Patent expirations.
- Ongoing: Reliance on key products like DARZALEX.
Oportunidades de crecimiento
- Expansion of DARZALEX: DARZALEX, Genmab's leading product for multiple myeloma, has significant growth potential through label expansions and increased market penetration. The global multiple myeloma market is projected to reach $37.5 billion by 2028, providing a substantial opportunity for Genmab to increase its revenue. The company is actively pursuing clinical trials to evaluate DARZALEX in new indications and combinations, which could further drive growth.
- Commercialization of Epcoritamab: Epcoritamab, a bispecific antibody being developed in collaboration with AbbVie, has the potential to become a significant growth driver for Genmab. Epcoritamab targets relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The market for lymphoma treatments is expected to grow, offering a substantial opportunity for Epcoritamab upon regulatory approval. The drug is currently under review by regulatory agencies.
- Advancement of Pipeline Assets: Genmab has a robust pipeline of antibody therapeutics in various stages of development, targeting a range of diseases. The successful advancement and commercialization of these pipeline assets could significantly expand Genmab's revenue base and market presence. The company's pipeline includes products such as Teclistamab, Camidanlumab tesirine, and several other preclinical and clinical programs.
- Strategic Collaborations: Genmab's strategic collaborations with leading pharmaceutical and biotechnology companies provide access to external expertise, resources, and markets. These collaborations can accelerate the development and commercialization of Genmab's antibody therapeutics and expand its global reach. The company's collaborations with AbbVie, Janssen, and other partners are expected to contribute to its long-term growth.
- Geographic Expansion: Genmab has the opportunity to expand its geographic presence and market its products in new regions. The company currently operates primarily in Denmark, but its products are marketed globally through partnerships. Expanding into new markets, such as Asia and Latin America, could significantly increase Genmab's revenue and market share. The company may need to establish local infrastructure and partnerships to succeed in these new markets.
Oportunidades
- Expansion of DARZALEX into new indications.
- Commercialization of pipeline assets like epcoritamab.
- Geographic expansion into new markets.
- Strategic acquisitions and partnerships.
Amenazas
- Competition from other biotechnology companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent expirations.
Ventajas competitivas
- Proprietary antibody therapeutics platform.
- Strong pipeline of innovative products.
- Strategic collaborations with leading pharmaceutical companies.
- Established market presence with marketed products like DARZALEX.
Acerca de GNMSF
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's initial focus was on developing human monoclonal antibodies, and it has since expanded its portfolio through strategic collaborations and internal research and development efforts. Genmab's marketed products include DARZALEX (daratumumab) for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Genmab's pipeline includes a range of products in various stages of development, targeting hematological malignancies and solid tumors. These include GEN1047, tisotumab vedotin (co-developed with Seagen Inc.), DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, Epcoritamab (developed in collaboration with AbbVie), HexaBody-CD38, and DuoHexaBody-CD37. The company also has several products in Phase 2 clinical trials, such as Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. Genmab has established collaborations with several leading pharmaceutical and biotechnology companies, including CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. These collaborations enable Genmab to leverage external expertise and resources to accelerate the development and commercialization of its antibody therapeutics. Genmab operates primarily in Denmark, with a global reach through its partnerships and marketed products.
Qué hacen
- Develops antibody therapeutics for cancer and other diseases.
- Markets DARZALEX for the treatment of multiple myeloma (MM).
- Markets teprotumumab for the treatment of thyroid eye disease.
- Markets ofatumurnab for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis.
- Markets Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Develops products for treating hematological malignancies and solid tumors.
- Collaborates with other companies to co-develop and commercialize antibody therapeutics.
Modelo de Negocio
- Develops and commercializes antibody therapeutics.
- Generates revenue through product sales and royalties.
- Collaborates with other companies to co-develop and commercialize products.
- Out-licenses its technology and products to generate revenue.
Contexto de la Industria
Genmab A/S operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The global biotechnology market is experiencing substantial growth, driven by increasing demand for novel therapeutics, advancements in antibody engineering, and a growing prevalence of cancer and other diseases. Genmab competes with other biotechnology companies, including ALPMF (Alphamab Oncology), ALPMY (Alphamab Oncology), BMXXY (BioMaxx Pharmaceuticals), GIKLY (Ginkgo Bioworks Holdings), and IVBXF (Invex Therapeutics), in the development and commercialization of antibody therapeutics. The company's strategic collaborations and differentiated technology platform position it favorably within the industry.
Clientes Clave
- Patients with cancer and other diseases.
- Hospitals and clinics.
- Pharmaceutical companies.
- Healthcare providers.
Finanzas
Gráfico e información
Precio de la acción de Genmab A/S (GNMSF): Price data unavailable
Últimas noticias
-
Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Here’s Why
defenseworld.net · 12 mar 2026
-
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
seekingalpha.com · 11 mar 2026
-
Transactions in Connection with Share Buy-back Program
Yahoo! Finance: GNMSF News · 9 mar 2026
-
Correction to Company Announcement No. 13 of March 2, 2026
Yahoo! Finance: GNMSF News · 2 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GNMSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GNMSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GNMSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Here’s Why
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Transactions in Connection with Share Buy-back Program
Correction to Company Announcement No. 13 of March 2, 2026
Liderazgo: Jan van de Winkel
CEO
Jan van de Winkel is the CEO of Genmab A/S. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions and has a strong track record in drug development and commercialization. Van de Winkel's expertise spans from early-stage research to late-stage clinical development and market access. He is known for his strategic vision and ability to drive innovation within the biotechnology sector.
Historial: Under Jan van de Winkel's leadership, Genmab A/S has achieved significant milestones, including the successful development and commercialization of DARZALEX and other antibody therapeutics. He has overseen the expansion of Genmab's pipeline and the establishment of strategic collaborations with leading pharmaceutical companies. Van de Winkel's leadership has been instrumental in driving Genmab's growth and establishing its position as a leading biotechnology company.
Información del mercado OTC de GNMSF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Genmab A/S (GNMSF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of stringent listing requirements and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure, making it difficult to assess the company's financial health.
- Lower liquidity, leading to wider bid-ask spreads and greater price volatility.
- Less regulatory oversight compared to companies listed on major exchanges.
- Potential for fraud or manipulation due to the lack of stringent listing requirements.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established partnerships with reputable pharmaceutical companies.
- Marketed products with regulatory approvals.
- Experienced management team with a track record in the biotechnology industry.
- Presence in a regulated industry (healthcare).
- Publicly available information and press releases.
Lo Que los Inversores Preguntan Sobre Genmab A/S (GNMSF)
¿Cuáles son los factores clave para evaluar GNMSF?
Genmab A/S (GNMSF) actualmente tiene una puntuación IA de 55/100, indicando puntuación moderada. Fortaleza clave: Innovative antibody therapeutics platform.. Riesgo principal a monitorear: Potential: Clinical trial failures.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GNMSF?
GNMSF actualmente puntúa 55/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GNMSF?
Los precios de GNMSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GNMSF?
La cobertura de analistas para GNMSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GNMSF?
Las categorías de riesgo para GNMSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GNMSF?
La relación P/E para GNMSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GNMSF sobrevalorada o infravalorada?
Determinar si Genmab A/S (GNMSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GNMSF?
Genmab A/S (GNMSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- AI analysis pending for GNMSF.
- OTC market data may be less reliable than exchange-listed data.